Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Carboplatino o Olaparib per il cancro alla prostata con deficit di BRcA (COBRA)

12 novembre 2026 aggiornato da: VA Office of Research and Development

Uno studio di fase II multicentrico in aperto per confrontare l'efficacia del carboplatino come prima linea seguito da olaparib di seconda linea rispetto a olaparib come prima linea seguito da carboplatino di seconda linea nel trattamento di pazienti con carcinoma prostatico resistente alla castrazione contenente ricombinazione omologa Carenza

This is an unblinded, randomized clinical study comparing the efficacy of DNA damaging chemotherapy using carboplatin, to standard of care therapy for patients who have metastatic castrate resistant prostate cancer. This trial will use olaparib or carboplatin as initial therapy with crossover to the alternate or second-line drug after first progression for patients with tumors containing BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L inactivating mutations.

Participants are randomized (1:1) and receive either carboplatin (AUC 5, IV) every 21 days, first or olaparib taken orally (300 mg), twice daily in 28 day cycles, until intolerance, complete response, or progression by Prostate Cancer Working Group 3 (PCWG3) criteria.

Participants then crossover from the first-line therapy to the second-line therapy with the opposite study medication and receive treatment to intolerance or progression (whichever is first). Enrolled participants will be allowed to crossover to second line therapy if they continue to meet initial eligibility criteria, and at least three weeks have elapsed since last administration of either carboplatin or olaparib. Throughout the study, safety and tolerability will be assessed. Progression will be evaluated with bone scan, CT of the abdomen/pelvis, or MRI and PSA as per PCWG3 criteria.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Study General Trial Over-view

This study is designed to help better understand treatment options compared to standard therapies for patients who have targeted DNA repair mutations and metastatic castrate resistant prostate cancer (mCRPC).

Cancer therapies are aimed at finding a way to kill the cancer cells while causing minimal damage to normal (non-cancer) cells. This often works because cancers cells grow faster than many normal cells, many treatments are aimed at to take advantage of that difference. One of the ways to do this is to damage the DNA of these more rapidly growing cells. However, if the cells have a way of repairing that damage then therapies may not work as well. Some research shows that when specific changes or mutations occur in the genes involved with repairing DNA damage, resulting cancers have responded well to drugs which damage DNA.

Olaparib is known as a PARP inhibitor and is standard of care therapy for men with BRCA altered mCRPC. Carboplatin is a synthetic antineoplastic agent which has been used in the treatment of solid tumors and BRCA related cancers. When mutations occur in critical DNA-repair genes, research has found that treatment with carboplatin is also effective.

This research is being done to determine the response of mCRPC in patients with DNA repair mutations to treatment with olaparib compared to carboplatin. This study will test whether giving one drug or the other a has a better response.

Patients wishing to participate in this study are screened for safety and health eligibility before enrolling.

This study is enrolling 100 male participants total, from across the VAMC nationally who have the following:

  • Metastatic castration-resistant prostate cancer (mCRPC)
  • Cancer that has gotten worse, after any number of first-line treatments
  • Mutations in DNA-repair genes discovered as part of a patient's routine care.

Once eligibility is determined, enrolled participants are randomized into one of two groups:

  • Group A will start with carboplatin (IV) first, given every 21 days, then have the option to switch to the second treatment with olaparib taken daily, (orally) with cycles of every 28 days.
  • Group B will start with olaparib first, taken (orally), with 28 day cycles, then have the option to switch to the second treatment with carboplatin (IV) every 21 days.

Both study drugs in this trial are currently FDA approved, and are prescribed at the participating VAMC clinical sites per institutional guidelines. Carboplatin given in IV is also given as prescribed at the participating VAMC, and administered per institutional guidelines.

Participants are monitored for health and body function, cancer progression, toxicity and life quality at every visit during the trial and at an end of treatment visit (28 days after completion of the trial or after withdrawal). For participants who respond well to treatment during the trial, additional treatment cycles may be added and the study can be extended. Participants who experience intolerable toxicity, cancer progression, or whose doctors decide to change treatment, will either be switched to the opposite study drug or withdrawn from the study.

This important trial is designed to compare response rate and duration of response using carboplatin compared to olaparib in patients who have mCRPC which contains DNA repair gene mutations.

Tipo di studio

Interventistico

Iscrizione (Stimato)

100

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

    • California
      • West Los Angeles, California, Stati Uniti, 90073
        • Reclutamento
        • VA Greater Los Angeles Healthcare System, West Los Angeles, CA
        • Contatto:
    • Colorado
      • Aurora, Colorado, Stati Uniti, 80045
        • Reclutamento
        • Rocky Mountain Regional VA Medical Center, Aurora, CO
        • Contatto:
    • District of Columbia
      • Washington D.C., District of Columbia, Stati Uniti, 20422-0001
        • Reclutamento
        • Washington DC VA Medical Center, Washington, DC
        • Contatto:
    • Florida
      • Bay Pines, Florida, Stati Uniti, 33744-0000
        • Terminato
        • Bay Pines VA Healthcare System, Pay Pines, FL
      • Orlando, Florida, Stati Uniti, 32827
        • Reclutamento
        • Orlando VA Medical Center, Orlando, FL
        • Contatto:
    • Georgia
      • Decatur, Georgia, Stati Uniti, 30033
        • Reclutamento
        • Atlanta VA Medical and Rehab Center, Decatur, GA
        • Contatto:
          • Wayne Harris, MD
          • Numero di telefono: 206147 404-321-6111
    • Idaho
      • Boise, Idaho, Stati Uniti, 83702
    • Illinois
      • Chicago, Illinois, Stati Uniti, 60612
        • Terminato
        • Jesse Brown VA Medical Center, Chicago, IL
    • Michigan
      • Ann Arbor, Michigan, Stati Uniti, 48105
        • Reclutamento
        • VA Ann Arbor Healthcare System, Ann Arbor, MI
        • Contatto:
    • Minnesota
      • Minneapolis, Minnesota, Stati Uniti, 55417-2309
        • Reclutamento
        • Minneapolis VA Health Care System, Minneapolis, MN
        • Contatto:
    • Missouri
      • Kansas City, Missouri, Stati Uniti, 64128
        • Reclutamento
        • Kansas City VA Medical Center, Kansas City, MO
        • Contatto:
          • Bruce Montgomery
          • Numero di telefono: 206-277-6878
    • New York
      • New York, New York, Stati Uniti, 10010
        • Reclutamento
        • Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY
        • Contatto:
      • The Bronx, New York, Stati Uniti, 10468-3904
        • Terminato
        • James J. Peters VA Medical Center, Bronx, NY
    • North Carolina
      • Durham, North Carolina, Stati Uniti, 27705-3875
        • Reclutamento
        • Durham VA Medical Center, Durham, NC
        • Contatto:
    • Oregon
      • Portland, Oregon, Stati Uniti, 97239
        • Reclutamento
        • VA Portland Health Care System, Portland, OR
        • Contatto:
    • Pennsylvania
      • Philadelphia, Pennsylvania, Stati Uniti, 19106
        • Reclutamento
        • Philadelphia MultiService Center, Philadelphia, PA
        • Contatto:
    • Washington
      • Seattle, Washington, Stati Uniti, 98108-1532
        • Reclutamento
        • VA Puget Sound Health Care System Seattle Division, Seattle, WA
        • Investigatore principale:
          • Robert B. Montgomery, MD
        • Contatto:
    • Wisconsin
      • Madison, Wisconsin, Stati Uniti, 53705-2254
        • Reclutamento
        • William S. Middleton Memorial Veterans Hospital, Madison, WI
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Maschio

Descrizione

Inclusion Criteria:

  1. Signed study informed consent form (ICF) and HIPAA authorization form

  2. Diagnosis of prostate cancer (pure small-cell histology or pure high-grade neuroendocrine histology are excluded; neuroendocrine differentiation is allowed)

  3. Ongoing gonadal androgen deprivation therapy with gonadotropin-releasing hormone (GnRH) analogues, antagonists or orchiectomy. Patients who have not had an orchiectomy must be maintained on effective GnRH analogue/antagonist therapy

  4. mCRPC as defined by serum testosterone < 50 nanograms per milliliter (ng/ml) for patients on GnRH analogues or antagonists) and at least one of the following:

    • Prostate-specific antigen (PSA) level of at least 2 nanograms per milliliter (ng/ml) that has risen on at least 2 successive occasions at least 1 week apart
    • Evaluable disease progression by modified RECIST 1.1 (Response Evaluation Criteria in Solid Tumors)
    • Progression of metastatic bone disease on bone scan, CT or MRI with > 2 new lesions
  5. Prior therapy with abiraterone acetate, enzalutamide, apalutamide, or darolutamide

  6. Eastern Cooperative Oncology Group (ECOG) Performance Status of < 2 (see Appendix 3, ECOG Grading Scale)

  7. Results of previous standard DNA testing, or previous research testing, which confirms RAD51B, RAD51C, RAD51D, or RAD54L mutations (see Introduction, Section 2 for study design and previous research on targeted therapy) from primary, metastatic tumor or circulating tumor DNA, or pathogenic/likely pathogenic germline variant as assessed by a CLIA certified laboratory level assay for DNA sequencing.

  8. Patients must have normal organ and bone marrow function measured within 28 days prior to administration of study treatment as defined below:

    • Hemoglobin > 10.0 grams per deciliter (g/dL)
    • Absolute neutrophil count (ANC) > 1.5 x 109/liter (L)
    • Platelet count > 100 x 109/L
    • Total bilirubin < 1.5 x institutional upper limit of normal (ULN)
    • Aspartate aminotransferase (AST) (Serum Glutamic Oxaloacetic Transaminase (SGOT) / Alanine aminotransferase (ALT) (Serum Glutamic Pyruvate Transaminase (SGPT) < 2.5 x institutional upper limit of normal unless liver metastases are present in which case, they must be < 5x ULN
    • Patients must have creatinine clearance estimated using the Cockcroft-Gault equation of >51 mL/min: Estimated creatinine clearance =(140-age [years]) x weight (kg)/(serum creatinine (mg/dL) x 72)

Exclusion Criteria:

  1. Currently receiving active therapy for other neoplastic disorder(s)
  2. Concurrent enrollment in another clinical investigational drug or device study
  3. Histologic evidence of small cell carcinoma (morphology alone - immunohistochemical evidence of neuroendocrine differentiation without morphologic evidence is not exclusionary)
  4. Prior treatment with platinum, mitoxantrone or PARP inhibitor for castration resistant prostate cancer
  5. Known parenchymal brain metastasis
  6. Active or symptomatic viral hepatitis or chronic liver disease AST or ALT > 2.5 x ULN or total bilirubin > ULN (unless Gilbert's syndrome is the etiology of hyperbilirubinemia)
  7. Subjects with myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of MDS/AML
  8. Concomitant use of known strong CYP3A inhibitors (e.g. itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (e.g. ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required washout period prior to starting olaparib is 2 weeks
  9. Concomitant use of known strong (e.g. phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort) or moderate CYP3A inducers (e.g. bosentan, efavirenz, modafinil). The required washout period prior to starting olaparib is 5 weeks for phenobarbital and 3 weeks for other agents
  10. Subjects unable to swallow orally administered medication and subjects with gastrointestinal disorders likely to interfere with absorption of the study medication
  11. Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past 6 months, severe or unstable angina, or New York Heart Association (NYHA) Class II-IV heart disease or cardiac ejection fraction measurement of < 35 % at baseline
  12. Treatment with an investigational therapeutic within 30 days of Cycle-1
  13. Presence of dementia, psychiatric illness, and/or social situations limiting compliance with study requirements or understanding HIPAA authorization and/or giving of informed consent
  14. Any condition(s), medical or otherwise, which, in the opinion of the Investigators, would jeopardize either the patient or the integrity of the data obtained

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Ricerca sui servizi sanitari
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione incrociata
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: Treatment Arm 1 - Carboplatin to Olaparib

Participants are administered carboplatin AUC 5 IV first, which is administered Cycle-1, Day-1, and then every 21 days as first line therapy. For second line (crossover), olaparib is prescribed and taken orally at home, twice daily, 300 mg in 28 day cycles.

Chemotherapy FDA approved drug used to treat: ovarian, lung, head and neck cancers. It is sometimes used in combination with other medications or off-label use to treat other metastatic cancers.

Altri nomi:
  • Paraplatino

Olaparib is a targeted therapy drug that is used for mCRPC and is approved by the FDA for this use.

Altri nomi:
  • Lynparz
Comparatore attivo: Treatment Arm 2 - Olaparib to Carboplatin

Participants are prescribed olaparib which is taken orally at home, twice daily, 300 mg in 28 day cycles, as first line therapy. For second line (crossover), carboplatin is administered AUC 5 IV every 21 days thereafter.

Chemotherapy FDA approved drug used to treat: ovarian, lung, head and neck cancers. It is sometimes used in combination with other medications or off-label use to treat other metastatic cancers.

Altri nomi:
  • Paraplatino

Olaparib is a targeted therapy drug that is used for mCRPC and is approved by the FDA for this use.

Altri nomi:
  • Lynparz

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Progression-free survival (PFS-1L) defined as the time interval between randomization and first documented disease progression or death due to any cause reported during, or after, first-line treatment
Lasso di tempo: Through duration of the study, up to 100 weeks

Progression free survival (PFS) by bone scan or measurable disease, Response Evaluation Criteria in Solid Tumors (RECIST 1.1) to initial therapy (PFS-1L) with either study drug

Through duration of the study, up to 100 weeks

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Time interval between randomization and second documented disease progression during or after second-line or death (due to any cause)
Lasso di tempo: Through duration of the study, up to 100 weeks

Progression-free survival combined, a composite endpoint defined as the time interval between randomization and second documented disease progression reported during or after second-line or death due to any cause

Through duration of the study, up to 100 weeks
PSA measurements/response
Lasso di tempo: Through duration of the study, up to 100 weeks

To assess PSA response to initial therapy with carboplatin vs. olaparib

Through duration of the study, up to 100 weeks
PSA measurements/response
Lasso di tempo: Through duration of the study, up to 100 weeks

To assess PSA response duration to second line therapy with olaparib vs carboplatin

Through duration of the study, up to 100 weeks
Grade 3 and 4 toxicities in first and second-line setting
Lasso di tempo: Through duration of the study, up to 100 weeks

To assess Grade 3 and 4 toxicities for each regimen in the first- and second-line setting

Through duration of the study, up to 100 weeks
To assess cost effectiveness of carboplatin versus olaparib for the treatment of castration-resistant metastatic prostate cancer
Lasso di tempo: Through duration of the study, up to 100 weeks

To assess cost effectiveness of carboplatin versus olaparib for the treatment of castration-resistant metastatic prostate cancer

Through duration of the study, up to 100 weeks

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Exploratory Objective - PFS
Lasso di tempo: Through duration of the study, up to 100 weeks

To assess the PFS of patients who receive olaparib versus patients who receive carboplatin during the second-line of treatment (PFS-2L)

Through duration of the study, up to 100 weeks
Exploratory Objective - objective response rate
Lasso di tempo: Through duration of the study, up to 100 weeks

To assess the objective response rate in patients who receive olaparib versus patients who receive carboplatin during second-line of treatment.

Through duration of the study, up to 100 weeks
Exploratory Objective- objective duration of response
Lasso di tempo: Through duration of the study, up to 100 weeks

To assess the objective duration of response in patients who receive olaparib versus patients who receive carboplatin during second-line of treatment.

Through duration of the study, up to 100 weeks

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Investigatore principale: Robert B. Montgomery, MD, VA Puget Sound Health Care System Seattle Division, Seattle, WA
  • Investigatore principale: Maneesh Jain, MD, Washington DC VA Medical Center, Washington, DC
  • Investigatore principale: Phoebe Tsao, MD MSc, VA Ann Arbor Healthcare System, Ann Arbor, MI
  • Investigatore principale: Ryan Burri, MD, Bay Pines VA Healthcare System, Pay Pines, FL

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

1 ottobre 2019

Completamento primario (Stimato)

31 agosto 2027

Completamento dello studio (Stimato)

31 agosto 2027

Date di iscrizione allo studio

Primo inviato

26 luglio 2019

Primo inviato che soddisfa i criteri di controllo qualità

29 luglio 2019

Primo Inserito (Effettivo)

30 luglio 2019

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

16 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

12 novembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • ONCA-009-18F
  • CX-18-006 (Altro numero di sovvenzione/finanziamento: Veterans Affairs CSR&D Merit Review Award)
  • 19-08 (Altro identificatore: VA CIRB)
  • 01783 (Altro identificatore: MIRB (LSI))
  • 01781 (Altro identificatore: MIRB (National Chair))
  • 1I01CX001963-01 (Sovvenzione/contratto NIH degli Stati Uniti)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

Sì

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .